Emerald Advisers, LLC Akero Therapeutics, Inc. Transaction History
Emerald Advisers, LLC
- $2.41 Billion
- Q3 2024
A detailed history of Emerald Advisers, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Emerald Advisers, LLC holds 524,427 shares of AKRO stock, worth $14.8 Million. This represents 0.63% of its overall portfolio holdings.
Number of Shares
524,427
Previous 515,252
1.78%
Holding current value
$14.8 Million
Previous $12.1 Million
24.47%
% of portfolio
0.63%
Previous 0.54%
Shares
4 transactions
Others Institutions Holding AKRO
# of Institutions
190Shares Held
73.8MCall Options Held
241KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.9MShares$223 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$200 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$167 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$158 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$148 Million4.29% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.31B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...